Hemington Wealth Management Reduces Stock Position in Johnson & Johnson $JNJ

Hemington Wealth Management lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,294 shares of the company’s stock after selling 1,589 shares during the quarter. Johnson & Johnson accounts for 0.5% of Hemington Wealth Management’s portfolio, making the stock its 25th biggest holding. Hemington Wealth Management’s holdings in Johnson & Johnson were worth $3,405,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Apexium Financial LP raised its position in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 2,310 shares in the last quarter. Avanza Fonder AB raised its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after purchasing an additional 6,566 shares in the last quarter. Joel Isaacson & Co. LLC raised its position in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Finally, Absher Wealth Management LLC raised its position in Johnson & Johnson by 1.2% during the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock valued at $35,752,000 after purchasing an additional 2,469 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.1%

Shares of NYSE:JNJ opened at $190.88 on Tuesday. The business’s 50-day moving average is $178.88 and its 200 day moving average is $163.97. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10. The firm has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of brokerages have weighed in on JNJ. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Citigroup boosted their price target on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Bank of America boosted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.94.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.